What is the intrinsic value of TXMD?
As of 2025-12-16, the Intrinsic Value of TherapeuticsMD Inc (TXMD) is
0.65 USD. This TXMD valuation is based on the model Peter Lynch Fair Value.
With the current market price of 1.70 USD, the upside of TherapeuticsMD Inc is
-61.61%.
Is TXMD undervalued or overvalued?
Based on its market price of 1.70 USD and our intrinsic valuation, TherapeuticsMD Inc (TXMD) is overvalued by 61.61%.
TXMD Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(4,829.95) - (906.85) |
(1,512.72) |
-89083.7% |
| DCF (Growth 10y) |
(41,023.81) - (229,021.35) |
(70,058.86) |
-4121209.4% |
| DCF (EBITDA 5y) |
(487.93) - (632.89) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(22,323.25) - (30,489.10) |
(1,234.50) |
-123450.0% |
| Fair Value |
0.65 - 0.65 |
0.65 |
-61.61% |
| P/E |
0.17 - 0.79 |
0.34 |
-79.7% |
| EV/EBITDA |
1.48 - 1.73 |
1.70 |
0.1% |
| EPV |
0.97 - 1.05 |
1.01 |
-40.7% |
| DDM - Stable |
0.25 - 0.86 |
0.56 |
-67.3% |
| DDM - Multi |
(327.08) - (859.56) |
(474.15) |
-27990.9% |
TXMD Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
19.67 |
| Beta |
1.45 |
| Outstanding shares (mil) |
11.57 |
| Enterprise Value (mil) |
12.55 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.97% |
| Cost of Debt |
5.00% |
| WACC |
6.32% |